Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly's innovative culture and strong financial ... Lilly is developing a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... In the neuroscience space, Lilly has made significant strides with donanemab. The TRAILBLAZER-ALZ 6 trial showed positive results, bringing ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... for diabetes and weight loss, and Donanemab for Alzheimer’s disease.

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...